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ABSTRACT 
Aims: The mechanisms that drive breast cancer (BC) progression and poor outcome are not 
fully understood. The human heat shock protein 90 alpha family class A member 1 (HSP90α) 
encoded by the HSP90ΑA1 gene has a vital role in cellular responses to stress and is implicated 
in the development and progression of many cancers. The current study aims to explore the 
clinical and prognostic importance of HSP90α in BC. 
Methods: The Molecular Taxonomy of Breast Cancer International Consortium (n=1980); The 
Cancer Genome Atlas (n=1097) and the Breast Cancer Gene-Expression Miner (Bc-
GenExMiner) BC datasets (n=5056) were used to evaluate HSP90ΑA1 mRNA expression. 
HSP90α protein expression was further assessed using immunohistochemistry in a large 
(n=911) well-characterised BC series. The association between mRNA and protein expressions 
with other clinicopathological parameters and outcome was analysed. 
Results: High expression of HSP90ΑA1 both at the mRNA and protein levels was significantly 
associated with characteristics of BC poor prognosis, including high grade, lymphovascular 
invasion, poor Nottingham Prognostic Index and positive expression of p53 and PIK3CA. 
Outcome analysis revealed that high HSP90α protein expression is an independent predictor of 
shorter BC-specific survival. 
Conclusion: HSP90α can be used as a potential prognostic marker in BC. Further mechanistic 






Breast Cancer (BC) is a heterogeneous group of diseases with various presentations, 
morphological features, outcome and response to therapy (1). Although many factors that 
influence BC incidence and progression have been identified, current understanding of the 
diverse molecular and cellular mechanisms contributing to BC progression remains limited. A 
better knowledge of the factors involved in BC progression will help in tailoring personalised 
therapy and improving outcome (2). 
Existing data indicate that the cellular stress response is important in cancer progression and 
cancer therapy (3). Expression of Heat Shock Proteins (HSPs) increases in response to cellular 
stress (4, 5) and can enable tumour cells to survive cellular stress by evading cell death and 
senescence mechanisms (6). Consistent with this, it was demonstrated that HSPs have an 
essential role in multiple pro-oncogenic signalling pathways, and it is an Adenosine 
Triphosphate (ATP) dependent protein chaperone (7, 8). Subsequently, the heat shock protein 
90 (HSP90) family has attracted considerable attention as a potential therapeutic target (9) as 
these proteins are the key players involved in protein modification and have been implicated 
in BC progression (10). The human HSP90 alpha family class A member 1 (HSP90α), encoded 
by the HSP90ΑA1 gene, appears to be critically important in the prevention of cell death (11) 
and evasion of apoptosis (12). Previous studies have indicated that HSP90α overexpression 
inhibits major apoptosis associated proteins in leukaemia, enabling the malignant cells to 
escape apoptosis and undergo proliferation (13, 14). Consistent with this, mechanistic evidence 
from a lung cancer model indicates HSP90α role in tumour growth (15). 
Autophagy can induce genomic instability, malignant transformations and may help metastatic 
cancer cells to escape from anoikis (16, 17). In vitro studies in osteosarcoma have also shown 
that HSP90ΑA1 knockdown increased chemo-sensitivity by decreasing autophagy activity of 
cancer cells (18), which raises the potential that HSP90α also contributes to pro-invasive 
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mechanisms. Taken together, this study aimed to investigate the clinical and prognostic value 
of HSP90α expression, at both mRNA and protein levels, in BC and relating these findings to 
key clinicopathological factors and the expression of other proteins relevant to HSP90α 
function. 
 
MATERIAL AND METHODS 
HSP90ΑA1 mRNA expression 
The clinical significance of HSP90ΑA1 mRNA expression was assessed using the Molecular 
Taxonomy of Breast Cancer International Consortium (METABRIC) dataset of invasive BC 
(n=1980) (19, 20). The clinicopathological associations and prognostic value of HSP90ΑA1 
mRNA expression were further evaluated using BC cohort of The Cancer Genome Atlas 
(TCGA)- Breast Invasive Carcinoma BRCA (n=1097) (21) and the Breast Cancer Gene-
Expression Miner v4.5 (Bc-GenExMiner v4.5) datasets (n= 5,056) (22). 
 
HSP90α protein expression 
This study included a well-characterised cohort of invasive BC (n=911) collected from the 
Nottingham City Hospital, Nottingham, UK. Treatment data and consequent outcome were 
maintained and updated. The outcome data included breast cancer-specific survival (BCSS) 
and distant metastasis-free survival (DMFS). The BCSS was defined as duration (in months) 
from primary surgical treatment until the time of death due to BC. DMFS refers to the duration 
(in months) from primary surgical treatment until the first distant metastasis (23). Nottingham 
Prognostic Index (NPI) was used to risk stratify and manage patients (24), where the good 
prognostic group (NPI ≤3.4) received no therapy while all patients with ER-positive tumours 
and had moderate and poor NPI (>3.4) received adjuvant hormonal therapy (HT). The poor 
prognostic NPI group of ER-negative patients were offered chemotherapy if fit. HT coupled 
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with chemotherapy was given to patients with both ER and lymph node (LN) positive patients 
(25). A total of 330 patients (36%) received HT, and 165 (18%) were given chemotherapy. 
Patients` characteristics of the 911 cases are summarised in Supplementary Table 1. 
 
Immunohistochemistry (IHC) 
To validate the antibody-specificity, western blotting was performed using the anti-HSP90α 
antibody (ab13492; Abcam, Cambridge, UK) with a dilution of 1:700. The house-keeping 
rabbit monoclonal anti-β-Actin (ab13492; Abcam, Cambridge, UK) was used at a dilution of 
1:5000. For western blotting, cell lysates from HeLa, MCF7, SKBr3 and MDA-MB-231 (all 
from The American Type Culture Collection; Rockville, MD, USA) were used. A single 
specific band at the predicted molecular weight (90 kDa; Supplementary Fig.1a) confirmed the 
specificity of the antibody. Full-face BC tissue sections (n=14) that were selected based on 
lymphovascular invasion (LVI) status, tumour grades, and histological type, were stained using 
IHC to evaluate the pattern of HSP90α protein expression before staining of Tissue 
Microarrays (TMAs). TMA was constructed from the study cohort, as previously described 
(26). HSP90α protein expression was assessed by IHC using the Novolink Max Polymer 
Detection system (Leica, Newcastle, UK). Anti-HSP90α primary antibody, diluted at 1:200, 
was incubated for 1 hour at room temperature. 
 
Scoring of protein expression 
HSP90α stained slides were scanned into high-resolution digital images using a high 
throughput digital scanner (NanoZoomer, Hamamatsu Photonics) (27). The images were 
viewed at 20x magnification using Xplore image viewer software (Philips, UK). Only cores 
that contained adequate tumour tissue (at least 15% of the invasive tumour relative to the whole 
core area) were scored. About one-third of cases were excluded due to loss of cores (during 
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TMA sectioning, processing and/or during IHC staining process) or presence an insufficient 
tumour tissue (<15% of the core surface area) for assessment. The modified ‘H-Score’ method 
was used semiquantitative evaluation taking the percentage (0-100) and the intensity (0 -
negative, 1 -weak, 2 -moderate and 3 -strong) of stained cells into consideration (28). For 
interobserver concordance, a subset of cores (25%) was independently scored by another 
scorer, (MT) and interclass correlation coefficient (ICC) was performed (ICC=0.7). Scoring 
was performed on anonymised samples of clinical variables at the time of scoring. Discordant 
cases were re-scored by both observers, and a final score was agreed.  
BC molecular subtypes were defined according to their IHC profile as Luminal-A: ER+, 
PR+/HER2-, Luminal-B (ER+/HER2- with high proliferation (Ki67≥10%) or ER+/HER2+ 
regardless the proliferation index), HER2-enriched (HER2+ and ER-, PR-), and Triple-
negative breast cancer (TNBC) (ER-, PR- and HER2-). Data on biomarkers related to EMT, 
progression and metastasis of BC, including N-cadherin, Ki67, PIK3CK kinase, tumour 
suppressor protein p53, AKT and epidermal growth factor receptor was available and used in 




SPSS 24 (IBM, Chicago, IL, USA) was used to perform the statistical analysis. For HSP90ΑA1 
mRNA expression, the median value was used to dichotomise the data. For the HSP90α protein 
expression, the cut-off point was determined as H-score 50 using the median, with a score >50 
was considered high expression. The association between HSP90α expression and the 
clinicopathological factors was evaluated using the Chi-square test. The univariate survival 
analysis was conducted using Kaplan Meier plots, and multivariate survival analyses were 
obtained using Cox regression model with adjustment of covariates was fitted to test 
 7 
independence from standard prognostic factors in BC. A p < 0.05 (two-tailed) was considered 
significant. Correlation between HSP90AA1 mRNA and protein expression was analysed with 
Spearman’s coefficient correlation test, using the subset of the Nottingham series included in 
METABRIC study (n=153). 
This study was approved by the Nottingham Research Ethics Committee 2 (under the title: 
Development of molecular genetic classification of BC) reference number REC202313. This 
study was conducted in accordance with the Declaration of Helsinki, and informed consent was 
obtained from all patients who participated in the study. 
 
RESULTS 
HSP90ΑA1 mRNA expression 
High expression of HSP90ΑA1 mRNA, as defined using median cut off, was seen in (990 of 
1980 cases) in METABRIC. A similar frequency of positivity was seen in the TCGA-BRCA 
(549 of 1097 cases) and the Bc-GenExMiner v4.5 datasets (2537 of 5056 cases). High 
expression of HSP90ΑA1 mRNA was significantly associated with high grade, LVI-positivity, 
ER-negativity and HER2-positivity (Table 1a). HSP90ΑA1 mRNA expression was 
significantly higher in luminal B, HER2-positive and TNBC than luminal A tumours (Table 
1a), and it was associated with high PIK3CA and p53 (Table 1b). Previously stated data was 
seen in both METABRIC and TCGA-BRCA. 
Outcome analysis revealed that patients who had BC with higher HSP90ΑA1 mRNA 
expression had significantly shorter BCSS than those with low HSP90ΑA1 expression 
(HR=1.38; 95% CI=1.16-1.65, p = 0.0004; and HR=1.85; 95% CI=1.318-2.61, p<0.0001 in 
METABRIC and TCGA data respectively; Fig.1a and b). Using the prognostic module of Bc-
GenExMiner v4.5, HSP90ΑA1 mRNA was validated as a significant prognostic factor for 
shorter survival (HR=1.17; 95% CI=1.07-1.28, p = 0.0004; Supplementary Fig.1b). 
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HSP90α protein expression and its association with the clinicopathological parameters  
HSP90α staining was homogeneously distributed within the invasive tumour cells in the full-
face tissue sections. HSP90α expression in invasive BC and adjacent normal terminal duct-
lobular units (TDLUs) are illustrated in (Fig.2a-b). HSP90α showed cytoplasmic 
immunoreactivity and a positive linear correlation with HSP90AA1 mRNA (Spearman’s 
coefficient 0.3; p=0.001). The normal TDLUs adjacent to the tumour showed uniformly weak 
HSP90α staining compared to invasive cancer cells. 
High HSP90α protein expression was observed in 58% of cases and was significantly 
associated with high tumour grade (p < 0.0001), positive nodal status (p = 0.0016), positive 
LVI (p = 0.014), high PIK3CA (p < 0.0001) and positive p53 (p < 0.002), Table 2. HSP90α 
was highly expressed in Luminal-B / HER2-negative, TNBC, Luminal-B / HER2-positive and 
HER2-enriched subtypes while Luminal-A tumours showed the lowest levels of expression 
(p=0.002), Table 2. 
Outcome analysis 
Cases with high HSP90α protein expression had significantly shorter BCSS than those with 
low HSP90α expression (HR=1.45; 95% CI=1.17-1.89, p = 0.005; Fig.3a). In addition, cases 
with high HSP90α expression displayed significantly shorter DMFS (HR= 1.35; 95% CI 1.65-
1.74, p = 0.013; Fig.3b). High expression of HSP90α in Luminal-B / HER2-negative cohort 
was associated with shorter BCSS and DMFS (p = 0.002, p = 0.009, respectively; 
Supplementary Fig.2a-b).  There was a similar trend observed in TNBC cases, while there was 
no association with outcome in the other molecular classes. Multivariate Cox regression 
analysis for HSP90α, adjusting for standard prognostic parameter including tumour size, nodal 
stage and LVI, showed that high HSP90α protein expression was an independent poor 
prognostic factor for shorter BCSS (HR=1.38; 95% CI=1.06-1.80, p = 0.018), and DMFS 
(HR=1.32; 95% CI=1.03-1.69, p = 0.027; Supplementary Table 2). 
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DISCUSSION 
BC is a group of heterogeneous diseases that differ in morphological, molecular, and clinical 
behaviour. This heterogeneity poses challenges in understanding the biology and the 
mechanisms underlying BC progression (2). BC risk stratification and prediction of the 
usefulness of different therapeutic protocols currently depend on the tumour 
clinicopathological criteria in addition to clinically validated biomarkers such as ER, PR and 
HER2. However, substantial proportions of patients with apparently similar 
clinicopathological features can show variable outcomes and different responses to the same 
therapeutic regimens. HSP family of proteins have essential roles in multiple oncogenic 
signalling pathways, through acting to maintain cellular proteins in their correct configurations 
to ensure their stability (7, 8). HSP90α controls protein assembly with proven extracellular 
roles in wound healing and cancer (35, 36). Therefore, the functions of HSP90α confer a 
favourable mechanism used by cancer cells to facilitate cancer cell migration and metastasis 
(37, 38). Thus, we explored the expression of HSP90α in multiple BC datasets at mRNA and 
protein level to correlate with clinicopathological parameters and prognostic utility. The 
current study shows that high expression of HSP90α is associated with poor prognostic 
parameters and an independent prognostic marker of poor clinical outcome. 
 
Our results showed that high expression of HSP90ΑA1 mRNA was significantly associated 
with clinicopathological variable characteristics of poor prognosis, including high histological 
grade, higher NPI prognostic scores, and loss of hormone receptor expression. Importantly, the 
expression was associated with shorter patients’ survival, independent of other variables. These 
results are in line with the findings from a recent study investigating the mRNA expression of 
six HSPs in BC and reported an association between HSP90ΑA1 and poor prognosis (6). 
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Patients with non-small cell lung cancer and lung adenocarcinoma showed that high mRNA 
expression of HSP90ΑA1 is associated with poor outcome (39). 
 
The positive correlation of HSP90α with PIK3CA and p53 expression, (40, 41) indicates that 
high HSP90α expression is associated with aggressive BC. PIK3CA is an EMT-promoting 
protein that contributes to the cell cycle control and interacts with HSP90 leading to apoptosis 
inhibition (4, 42). During the cell cycle, the active form of PIK3CA can phosphorylate the 
regular component of the membrane PIP2 to PIP3 which in turn activates AKT protein kinase 
B that interacts with HSP90 leading to inhibition of apoptosis. In vivo studies have reported 
the increased sensitivity of the cells to an apoptosis inducing stimulus by inhibiting AKT-
HSP90 binding (43, 44). These results were supported by another study that showed HSP90 
inhibition enhances AKT dephosphorylation process (45). In vitro and in vivo experiments 
have also concluded that PI3K/AKT is a major contributing signalling pathway in Burkitt 
lymphoma (40). Wild type p53 is well known as a tumour suppressor, whereas mutant p53 
seems to acquire oncogenic phenomenon (46, 47). Interestingly, the activation of HSP90 
expression induces stabilisation of mutant p53, consequently promoting tumour progression 
and metastases through the Hsp90-p53 co-binding mechanism (41, 48). 
 
Lymph node stage and LVI in BC are strong prognostic factors (49) predicting patient outcome. 
In our study, HSP90ΑA1 mRNA and protein expression was strongly associated with LVI 
positivity and positive nodal stage. Luminal B, TNBC and HER2 enriched BC molecular 
subtypes are biologically and clinically aggressive subtypes compared to luminal A tumours 
(50-52). Our results showed that HSP90α is less expressed in the Luminal-A BC molecular 
subtype than the Luminal-B / HER2-negative, Luminal-B / HER2-positive, HER2 enriched 
and TNBC classes. This could reflect the potential interaction between HSP90α expression, 
 11 
tumour proliferation, and HER2 signalling pathway, which may trigger invasion and LVI 
resulting in BC metastasis (53). In line with our findings, clinical trials of HSP90 inhibitors 
have shown promising results in the Luminal B and HER2-positive tumours (54). 
In conclusion, the current results highlighted the significant association of HSP90α with poor 
prognosis in BC patients and especially in the intrinsic subtypes of aggressive behaviour 
including Luminal B. Functional studies are required to determine the influence of aberrant 
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Table 1a Association between HSP90ΑA1 mRNA expression and clinicopathological 

















 METABRIC cohort TCGA cohort 
Parameters    












<2cm 451 (52.6) 407 (47.4) 
0.041 
99 (55.9) 78 (44.1) 
0.01 
≥ 2cm 528 (47.9) 574 (52.1) 273 (45.7) 325 (54.3) 
Histological grade 
Grade 1,2 534 (56.8) 406 (43.2) 
< 0.0001 
158 (59.0) 110 (41.0) 
< 0.0001 
Grade 3 405 (42.5) 547 (57.5) 67 (33.7) 132 (66.3) 
Nodal status 
Negative 542 (52.4) 493 (47.6) 
0.026 
423 (47.0) 477 (53.0) 
0.564 
Positive 444 (47.3) 494 (52.7) 10 (47.6) 11 (52.4) 
Lymphovascular invasion  
Negative 505 (54.3) 425 (45.7) 
0.017 
324 (58.0) 235 (42.0) 
< 0.0001 
Positive 306 (48.2) 329 (51.8) 127 (43.1) 168 (56.9) 
Oestrogen receptor status  
Negative 215 (45.4) 259 (54.6) 
0.02 
100 (42.0) 138 (58.0) 
0.001 
Positive 775 (51.5) 731 (48.5) 431 (53.5) 375 (46.5) 
Progesterone receptor status  
Negative 459 (48.8) 481 (51.2) 
0.32 
148 (43.0) 196 (57.0) 
< 0.0001 
Positive 531 (51.1) 509 (48.9) 380 (54.5) 317 (45.5) 
HER2 
Negative 897 (51.8) 836 (48.2) 
< 0.0001 
311 (53.2) 274 (46.8) 
< 0.0001 
Positive 93 (37.7) 154 (62.3) 61 (34.5) 116 (65.5) 
Nottingham prognostic index 
GPG 390 (57.4) 290 (42.6) 
< 0.0001   MPG 510 (46.3) 591 (53.7) 
PPG 90 (45.2) 109 (54.8) 
Molecular subtypes 
Luminal A 430 (59.9) 288 (40.1) 
< 0.0001 
301 (60.3) 198 (39.7) 
< 0.0001 
Luminal B 169 (34.6) 319 (65.4) 59 (29.9) 138 (70.1) 
HER2 
enriched 
105 (43.8) 135 (56.3) 16 (20.5) 62 (79.5) 
Basal-like 148 (45.0) 181 (55.0) 74 (43.3) 97 (56.7) 
Normal-
like 
134 (67.3) 65 (32.7) 30 (83.3) 6 (16.7) 
Values in bold are statistically significant. 
GPG, good prognostic group; METABRIC, The Molecular Taxonomy of Breast Cancer International Consortium; MPG, 
moderate prognostic group; PPG, poor prognostic group; TCGA, The Cancer Genome Atlas. 
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Table 1b Association between HSP90ΑA1 mRNA expression and other Gene of Interest in the 

































































 990 (50) 990 (50) 
920 1060 -5.4 <0.001 
548(49.9) 549 (50) 
443 654 -11 <0.001 
N-Cadherin 967 1013 -1.78 0.075 506 591 -4.4 <0.001 
PIK3CA 982 998 -3.15 0.002 483 614 -6.9 <0.001 
P53 941 1039 -3.8 <0.001 550 547 -0.1 0.889 
AKT 981 999 -0.72 0.471 506 591 -4.4 <0.001 
EGFR 1011 969 -1.66 0.096 554 543 -0.6 0.558 
Values in bold are statistically significant. 
EGFR, Epidermal Growth Factor Receptor; METABRIC, The Molecular Taxonomy of Breast Cancer International Consortium; PIK3CA, 







Table 2 Associations between HSP90α protein expression and the clinicopathological factors 
 
Factors   
Expression of HSP90α 
Low N (%) High N (%) p-value 
Tumour size 
≤ 2cm 190 (43.9) 243 (56.1) 
0.435 
> 2cm 195 (41.3) 277 (58.7) 
Histological grade 
Grade 1,2 234 (50.6) 228 (49.4) 
< 0.0001 
Grade 3 150 (34.1) 290 (65.9) 
Nodal status 
Negative 255 (45.6) 304 (54.4) 
0.016 
Positive 130 (37.5) 217 (62.5) 
Lymphovascular invasion  
Negative 271 (45.5) 325 (54.5) 
0.014 
Positive 114 (37.0) 194 (63.0) 
Oestrogen receptor status  
Negative 85 (37.8) 140 (62.2) 
0.126 
Positive 296 (43.6) 383 (56.4) 
Progesterone receptor status  
Negative 144 (39.9) 217 (60.1) 
0.534 
Positive 215 (42.0) 297 (58.0) 
Nottingham prognostic index  
GPG 149 (53.8) 128 (46.2) 
< 0.0001 MPG 182 (38.6) 290 (61.4) 
PPG 51 (34.5) 97 (65.5) 
Molecular subtypes 
Luminal A 115 (54.0) 98 (46.0) 
0.002 
Luminal B/HER2- 98 (36.3) 172 (63.7) 
Luminal B/HER2+ 16 (39.0) 25 (61.0) 
Triple Negative 57 (36.5) 99 (63.5) 
HER2 enriched 37 (42.0) 51 (58.0) 
Ki67 
Negative 107 (41.6) 150 (58.4) 
0.352 
Positive 163 (45.4) 196 (54.6) 
N-cadherin 
Negative 80 (43.5) 104 (56.5) 
0.35 
Positive 190 (39.5) 291 (60.5) 
PIK3CA 
Negative 95 (55.2) 77 (44.8) 
< 0.0001 
Positive 191 (36.1) 338 (63.9) 
P53 
Negative 278 (44.8) 342 (55.2) 
0.002 
Positive 83 (33.6) 164 (66.4) 
AKT 
Negative 59 (39.9) 89 (60.1 
0.861 
Positive 182 (39.1) 284 (60.9) 
EGFR  
Negative 300 (43.2) 395 (56.8) 
0.083 
Positive 66 (36.1) 117 (63.9) 
Values in bold are statistically significant. 
EGFR, Epidermal Growth Factor Receptor; GPG, good prognostic group; MPG, moderate prognostic group; 







Fig. 1: Cumulative survival of BC patients stratified by HSP90ΑA1 mRNA expression.  
Breast Cancer Specific Survival in the METABRIC cases was significantly worse in the high 
HSP90ΑA1 group than low HSP90ΑA1 expression (a) in the TCGA cases, significant 
differences were noted in patient survival in the HSP90ΑA1 high and low groups (b). BC, breast 
cancer; BCOS, breast cancer overall survival; BCSS, breast cancer-specific survival; TCGA, 






Fig. 2: HSP90α immunohistochemical protein expression in tissue microarray cores of normal 
and breast cancer tissue. Invasive cancer cells (strong staining in the cytoplasm of cancer cells) 







Fig. 3: Cumulative survival of BC patients stratified by HSP90α protein expression. 
BCSS (a) and DMFS (b) plots of cytoplasmic HSP90α revealed that high expression was 
associated with poor patient outcome. BC, breast cancer; BCSS, breast cancer-specific 












































































Cumulative survival of BC patients stratified by HSP90α protein expression.
Breast Cancer Specific Survival a) and distant metastasis free survival b) plots 
of cytoplasmic HSP90α revealed that high expression was associated with poor 
patient outcome in Luminal B HER2/negative subtype. 
 
 
Supplementary Table 1. Clinicopathological characteristics of the Nottingham primary 





Age at diagnosis (years) Number (%) 
≤50 316 (35%) 
>50 595 (65%) 
Menopausal status 
Premenopausal 354 (~39%) 
Postmenopausal 551 (~60%) 
Tumour size 
≤2.0 cm 433 (~48%) 
>2.0 cm 472 (~52%) 
Tumour grade 
1 145 (~16%) 
2 317 (~35%) 
3 440 (~48%) 
Nodal status 
Negative 559 (~61%) 
Positive 347 (~38%) 
Nodal stage 
1 557 (~61%) 
2 276 (~30%) 
3 70 (~8%) 
Lymphovascular invasion 
Negative 596 (~65%) 
Positive 308 (~34%) 
NPI 
Good prognostic group (GPG) 277 (~30%) 
Moderate prognostic group 
(MPG) 
472 (~52%) 
Pore prognostic group (PPG) 148 (~16%) 
Chemotherapy 
Yes 165 (~18%) 
No 709 (~78%) 
Endocrine therapy 
Yes 330 (~36%) 
No 546 (~60%) 
Supplementary Table 2. Multivariate Cox regression analysis for predictors of Breast cancer Specific Survival (BCSS) and Distant Metastasis 
free Survival (DMFS) based on clinicopathological factors and protein expression of HSP90α 
Factors 
Multivariate analysis BCSS Multivariate analysis DMFS  
Hazard 
Ratio 
95% CI p-value Hazard Ratio 95% CI p-value 
HSP90α expression 1.378 1.056-1.798 0.018 1.321 1.032-1.690 0.027 
Tumour size 1.62 1.225-2.136 0.001 1.725 1.338-2.224 <0.0001 
Axillary nodal stage 1.914 1.579-2.320 <0.0001 2.723 1.919-3.864 <0.0001 
Lymphovascular 
invasion 
1.46 1.106-1.905 0.007 0.647 0.387-1.081 0.096 
 
 
 
 
 
 
 
